Hilger, R A <br/><br/>
The Ras-Raf-MEK-ERK pathway in the treatment of cancer.  [electronic resource] 

 -  Onkologie  Dec 2002 
 - 511-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0378-584X 
<br/><br/><label>Standard No.: </label>10.1159/000068621  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--adverse effects<br/>Cell Division--drug effects<br/>Cell Survival--drug effects<br/>Clinical Trials, Phase I as Topic<br/>Humans<br/>MAP Kinase Kinase Kinase 1<br/>Mitogen-Activated Protein Kinases--antagonists & inhibitors<br/>Neoplasms--drug therapy<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-raf--antagonists & inhibitors<br/>Proto-Oncogene Proteins p21(ras)--antagonists & inhibitors<br/>Signal Transduction--drug effects